A new clinical trial conducted by researchers at the Medical University of Silesia in Katowice found that topical cannabidiol (CBD) gel significantly improved sleep quality and reduced migraine-related disability in individuals suffering from bruxism-associated muscle pain.
The randomized, double-blind study involved 60 participants divided into three groups: one received a placebo, while the others received either 5% or 10% CBD gel. Each participant applied the gel nightly for 30 days to the masseter muscles inside the mouth. Researchers assessed sleep quality using the Pittsburgh Sleep Quality Index (PSQI) and measured migraine-related disability with the Migraine Disability Assessment Scale (MIDAS).
Both CBD treatment groups showed marked improvements in sleep and migraine scores compared to the placebo group, with no significant difference between the 5% and 10% formulations. The CBD gels also led to measurable reductions in muscle tension, as confirmed by surface electromyography and a Bruxoff® device. Researchers noted a clear connection between reduced muscle activity and improved sleep and migraine outcomes.
The findings suggest that topical CBD may serve as a promising treatment for not only bruxism-related pain but also for associated issues such as poor sleep and migraines. Further studies are needed to explore long-term use and to refine dosing.
More articles from The Marijuana Herald can be found below.
